MF101 is in Phase 2 for quality of life conditions associated with menopause and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in ...

EMERYVILLE, Calif., Sept. 15 Bionovo, Inc.(Nasdaq: BNVI) today announced that its lead drug candidate, MF101, formenopausal hot flashes, showed improved sleep quality for women in a Phase 2study ...

"The availability of this robust high-throughput assay is a key to the fast and successful development of MF101," said Dr. Isaac Cohen, Bionovo's Chairman and Chief Executive Officer. "Having the tool ...

First things first -- Americans can keep dreaming on this one, as we're looking at yet another curious creation that probably won't wander far beyond the borders of South Korea. MyRacer's MF101 ...

EMERYVILLE, Calif., June 2, 2011 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and ...

BNVI announces its lead drug candidate, MF101, showed positive Phase 2 results for the treatment of hot flashes associated with menopause. Two hundred and seventeen women were enrolled in the co's ...

The games are of the Flash and/or Flash Lite variants and are loaded into either the devices 1GB of memory or an SD card. The same goes for music and movies as well as any other media this thing can ...

Bionovo, Inc. has begun enrollment for its single ascending dose pharmacokinetics clinical trial to further evaluate the company's drug candidate, MF101, designed to treat the symptoms of menopause.

What: Dr. Isaac Cohen, L.Ac., O.M.D., Chairman and CEO, and Dr. Mary Tagliaferri, M.D., President and Chief Medical Officer of Bionovo, Inc. (BNVI) will preside over ...